Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29; PMID: 25559415; https://doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, Westphalen CB, Strauch K. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med 2016; 5:2649-56; PMID: 27356493; https://doi.org/10.1002/cam4.767
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25; PMID: 21561347; https://doi.org/10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703; PMID: 24131140; https://doi.org/10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18:4266-76; PMID: 22896693; https://doi.org/10.1158/1078-0432.CCR-11-3114
   PubMed Web of Science ®Google Scholar
• Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S, Bruno M. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 2014; 40:513-22; PMID: 24315741; https://doi.org/10.1016/j.ctrv.2013.11.005
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7; PMID: 17404099; https://doi.org/10.1158/1078-0432.CCR-06-2746
   PubMed Web of Science ®Google Scholar
• Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, Laschinger M, W Büchler M, Friess H. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 2008; 268:98-109; PMID: 18486325; https://doi.org/10.1016/j.canlet.2008.03.056
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med 2016; 14:73; PMID: 27151159; https://doi.org/10.1186/s12916-016-0623-5
   PubMed Web of Science ®Google Scholar
• Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune therapy in GI malignancies: A review. J Clin Oncol 2015; 33:1745-53; PMID: 25918295; https://doi.org/10.1200/JCO.2015.60.7879
   PubMed Web of Science ®Google Scholar
• Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016; 4:14; PMID: 26981244; https://doi.org/10.1186/s40425-016-0119-z
   PubMed Web of Science ®Google Scholar
• Zheng L. PD-L1 expression in pancreatic cancer. J Natl Cancer Inst. 2017 Jan 28; 109(6); PMID: 28131993; https://doi/org/10.1093/jnci/djw304
   PubMedGoogle Scholar
• Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 2011; 17:1915-23; PMID: 21355078; https://doi.org/10.1158/1078-0432.CCR-10-0250
   PubMed Web of Science ®Google Scholar
• Finkelmeier F, Canli O, Tal A, Pleli T, Trojan J, Schmidt M, Kronenberger B, Zeuzem S, Piiper A, Greten FR et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer 2016; 59:152-9; PMID: 27039170; https://doi.org/10.1016/j.ejca.2016.03.002
   PubMed Web of Science ®Google Scholar
• Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, Le Gouill S, Haioun C, Tarte K, Lamy T et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014; 28:2367-75; PMID: 24732592; https://doi.org/10.1038/leu.2014.137
   PubMed Web of Science ®Google Scholar
• Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, Wu X, Cheng X, Xing X, Du H et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 2014; 26:104-11; PMID: 24653632; https://doi.org/10.3978/j.issn.1000-9604.2014.02.08
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Chen H, Wang WD, Chen XQ, Geng QR, Xia ZJ, Lu Y. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget 2015; 6:41228-36; PMID: 26515600; https://doi.org/10.18632/oncotarget.5682
   PubMed Web of Science ®Google Scholar
• Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol 2016; 142:1727-38; PMID: 27256004; https://doi.org/10.1007/s00432-016-2184-6
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016 Jul 2; 388(10039):73-85; PMID: 26830752; https://doi.org/10.1016/S0140-6736(16)00141-0
   PubMed Web of Science ®Google Scholar
• Kanemasa Y, Kamisawa T, Tabata T, Kuruma S, Iwasaki S, Chiba K, Kuwata G, Fujiwara T, Egashira H, Koizumi K et al. Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. Clin J Gastroenterol 2013; 6:459-64; PMID: 26182137; https://doi.org/10.1007/s12328-013-0416-8
   PubMedGoogle Scholar
• Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S. Prognostic relevance of CA 19–9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 2010; 31:351-7; PMID: 20480409; https://doi.org/10.1007/s13277-010-0044-6
   PubMed Web of Science ®Google Scholar
• Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S. Prognostic value of CA 19–9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013; 139:681-9; PMID: 23315099; https://doi.org/10.1007/s00432-012-1371-3
   PubMed Web of Science ®Google Scholar
• Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016; 22:9457-76; PMID: 27920468; https://doi.org/10.3748/wjg.v22.i43.9457
   PubMed Web of Science ®Google Scholar
• Sorensen SF, Demuth C, Weber B, Sorensen BS, Meldgaard P. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer 2016; 100:77-84; PMID: 27597284; https://doi.org/10.1016/j.lungcan.2016.08.001
   PubMed Web of Science ®Google Scholar
• Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006; 177:8844-50; PMID: 17142787; https://doi.org/10.4049/jimmunol.177.12.8844
   PubMed Web of Science ®Google Scholar
• Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol 2005; 235:109-16; PMID: 16171790; https://doi.org/10.1016/j.cellimm.2005.07.007
   PubMed Web of Science ®Google Scholar
• Lu C, Paschall AV, Shi H, Savage N, Waller JL, Sabbatini ME, Oberlies NH, Pearce C, Liu K. The MLL1-H3K4me3 Axis-Mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017 Jan 28; 109(6); PMID: 28131992; https://doi.org/10.1093/jnci/djw283
   PubMedGoogle Scholar
• Wang Y, Lin J, Cui J, Han T, Jiao F, Meng Z, Wang L. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. Oncotarget. 2017 Feb 7; 8(6):9354-9365; PMID: 28030840; https://doi.org/10.18632/oncotarget.14069
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID: 25428504; https://doi.org/10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg 2010; 34:1059-65; PMID: 20145927; https://doi.org/10.1007/s00268-010-0448-x
   PubMed Web of Science ®Google Scholar
• Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 2015; 3:1158-64; PMID: 26014095; https://doi.org/10.1158/2326-6066.CIR-15-0043
   PubMed Web of Science ®Google Scholar
• Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer 2014; 5:166-72; PMID: 24563671; https://doi.org/10.7150/jca.8167
   PubMed Web of Science ®Google Scholar
• Uruga H, Bozkurtlar E, Huynh TG, Muzikansky A, Goto Y, Gomez-Caraballo M, Hata AN, Gainor JF, Mark EJ, Engelman JA et al. Programmed Cell Death Ligand (PD-L1) expression in stage II and III lung Adenocarcinomas and nodal metastases. J Thorac Oncol. 2017 Mar; 12(3):458-466; PMID: 27815126; https://doi.org/10.1016/j.jtho.2016.10.015
   PubMed Web of Science ®Google Scholar
• Akahori H, Karmali V, Polavarapu R, Lyle AN, Weiss D, Shin E, Husain A, Naqvi N, Van Dam R, Habib A et al. CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury. Nat Commun 2015; 6:7792; PMID: 26242746; https://doi.org/10.1038/ncomms8792
   PubMed Web of Science ®Google Scholar
• Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA, Soonawalla Z, Liu S, McKenna WG, Muschel RJ et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016 Jul 5; 7(27):40992-41004; PMID: 27329602; https://doi.org/10.18632/oncotarget.10038
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID: 20842054; https://doi.org/10.1097/CJI.0b013e3181eec14c
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID: 22658128; https://doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67:9518-27; PMID: 17909062; https://doi.org/10.1158/0008-5472.CAN-07-0175
   PubMed Web of Science ®Google Scholar
• Balli D, Rech AJ, Stanger BZ, Vonderheide RH. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin Cancer Res. 2016 Dec 22; PMID: 28007776; https://doi.org/10.1158/1078-0432.CCR-16-2128
   PubMed Web of Science ®Google Scholar